Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Increase in the frequency of catheter-related bloodstream infections during the COVID-19 pandemic: a plea for control

M.J. Pérez-Granda a,b,c,d,*, C.S. Carrillo a, P.M. Rabadán a, M. Valerio a, M. Olmedo a, P. Muñoz a,b,c,e, E. Bouza a,b,c,e

a Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b CIBER de Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain
c Instituto de Investigación Sanitaria Gregorio Marañón (IIISGM), Madrid, Spain
d Department of Nursing, School of Nursing, Physiotherapy and Podiatry, Universidad Complutense de Madrid, Madrid, Spain
e Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain

ARTICLE INFO

Article history:
Received 10 June 2021
Accepted 25 September 2021
Available online 8 October 2021

Keywords:
COVID-19
Catheter-related bloodstream infections
Infection control
Nosocomial infections
COVID-19 secondary infections

SUMMARY

Background: The incidence of nosocomial infections including ventilator-associated pneumonia and bacteraemia has been described during the COVID-19 pandemic. However, information regarding the impact of COVID-19 on the incidence of catheter-related bloodstream infections (CR-BSIs) is very limited.

Aim: To evaluate the impact of the COVID-19 pandemic in the evolution of CR-BSIs in a large hospital.

Methods: This was a retrospective study comparing the incidence, aetiology and outcome of CR-BSIs during the months of March to May 2019 (pre-pandemic) and 2020 (during the pandemic).

Findings: The number of patients with one or more CR-BSIs in 2019 and 2020 were 23 and 58, respectively (1.89 vs 5.53/1000 admissions); \( P < 0.001 \). Median time from catheter implantation to demonstration of CR-BSI was 27.5 days (range 11.75–126.00 days) in the 2019 cases and 16.0 days (range 11.00–23.50 days) in the 2020 population (\( P = 0.032 \)).

Conclusions: A dramatic increase of CR-BSIs was found during the COVID-19 pandemic. Reinforcement of classic and new preventive measures is necessary.

© 2021 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Introduction

Catheter-related infection is one of the leading causes of bacteraemia and sepsis in developed countries and its adequate control by multi-disciplinary teams represents one of the best-quality indicators of an institution. The incidence can range from 0.8 to 18 episodes/1000 days of catheter exposure, depending on the type of patient, the type of catheter and the care provided during implantation and follow-up [1–5].

The COVID-19 pandemic has led to a huge increase in the workload of hospitals around the world and many patients have required long hospital stays including extended admissions to intensive care units (ICUs) [6–8].
Care for these patients has been provided under strenuous circumstances, not only because of the increased workload but also because sometimes there was a need to implicate staff with a sub-optimal degree of training with ICU patients [9–11]. Under these conditions, it is not surprising that an increased incidence of nosocomially acquired infections, including ventilator-associated pneumonia and bacteraemia, has been described in some centres [12–14]. Surprisingly, information regarding the impact of COVID-19 on the incidence of catheter-related bloodstream infections (CR-BSIs) is thus far limited.

Our aim was to evaluate the impact of the COVID-19 pandemic in the evolution of CR-BSIs in a large hospital, including incidence, aetiology and outcome.

Material and methods

Setting

Our institution is a general reference hospital, located in Madrid, Spain, with 1350 beds and approximately 55,000 admissions/year. The number of ICU beds is normally 70, but was expanded to 140 during the study period.

Study design

We performed a retrospective study in which we compared the incidence, aetiology, and outcome of CR-BSIs during the months of March to May in 2019 and 2020 (before and during the COVID-19 pandemic).

Ethics approval and consent to participate

The Ethics of Hospital General Universitario Gregorio Marañón approved the study. The need for informed consent for this study was waived by Ethics Committee MICRO.HGUGM.2020-030 of Hospital General Universitario Gregorio Marañón. All procedures were carried out in accordance with relevant guidelines and regulations.

Endpoints

The primary endpoint was the incidence of CR-BSI episodes before and during the pandemic. The secondary endpoints were the aetiology and consequences of CR-BSI during the first wave of the pandemic.

Definitions

CR-BSI

Presence of bacteraemia or fungaemia in a patient with clinical manifestations of infection and no other apparent source of bloodstream infection (with the exception of the catheter). A catheter-tip culture, quantitative or semi-quantitative, positive for the same micro-organism was also required [5,15].

Non—CR-BSI

In the present study, episodes of bacteraemia with a non-documented catheter origin.

Attributable mortality

In the present study, death occurring within 7 days after confirmation of CR-BSI in the absence of an alternative evident cause was considered as attributable.

Statistical analysis

Qualitative variables are expressed as a frequency distribution. Quantitative variables are expressed as the mean and standard deviation (SD) and as the median and interquartile range (IQR) if their distribution was skewed. Normally distributed continuous variables were compared using the t-test; non-normally distributed continuous variables were compared using the Mann–Whitney test. The chi-squared or Fisher exact test was used to compare categorical variables. Statistical significance was set at $P \leq 0.05$.

We compared the incidence rate of catheter-related bacteraemia per 1000 admissions between the two periods using Epidat version 3.1.

Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp, Armonk, NY, USA) and Epidat 3.1.

Results

Hospital admissions during the study periods (1st March to 31st May 2019 and 2020) were, respectively, 12,111 and 10,479 patients. Similarly, the number of blood cultures processed by the microbiology department was, respectively, 9520 (786.06/1000 admissions) and 8802 (839.96/1000 admissions) ($P < 0.001$), and the number of episodes of significant bloodstream infections was 358 (29.55/1000 admissions) and 379 (36.16/1000 admissions) in each three-month period in 2019 and 2020, respectively ($P = 0.007$). The rate of contaminated blood cultures was 2.8% and 3.8% ($P = 0.001$), before and during the pandemic.

The number of withdrawn catheters processed for culture in our laboratory was 302 (24.93/1000 admissions) in 2019 and 617 (58.87/1000 admissions) in 2020 ($P < 0.001$), and the number of positive catheter tips was 59 (4.87/1000 admissions) and 161 (15.36/1000 admissions) ($P = 0.066$), respectively, in 2019 and 2020 study periods.

The number of patients with one or more CR-BSIs increased significantly in 2020 (Figure 1) (23 and 58 (1.89 vs 5.53/1000 admissions); $P < 0.001$). The number of CR-BSI episodes in the study periods 2019 and 2020 was, respectively, 24 and 65 (1.98 vs 6.20/1000 admissions) ($P < 0.001$). The proportion of CR-BSIs from all significant episodes of bloodstream infections was 6.7% in 2019 and 17.1% in 2020 ($P < 0.001$).

The underlying conditions and characteristics of both populations are compared in Table 1. A high proportion of the cases of CR-BSI in 2020 occurred in COVID-19 patients (77.58%), and the vast majority of episodes occurred during their ICU stay (91.37%). The median ICU stay in patients with CR-BSIs was much longer in 2020 than in 2019 (35.0 (17.0–59.7) vs 17.0 (0.0–52.0); $P = 0.042$).

In 2019, 10 patients developed nosocomial infection (five of them had two or more infections): six urinary tract infections, eight respiratory infections, one surgical wound infection and one cytomegalovirus disease. Of these 10 patients, nine (90%) were in the ICU. In 2020, 47 patients developed nosocomial...
infection (22 had two or more infections): 15 urinary tract infection, 23 respiratory infections, one surgical wound infection, 13 cytomegalovirus disease, one *Clostridioides difficile* infection and six bloodstream infections. Forty-six patients (97.8%) were in the ICU.

The characteristics of the catheters in both populations are summarized in Table II. A large proportion of catheters in the 2020 patients were non-tunneled central lines (64.6%), and, of these, 78.6% were inserted into the jugular vein partially due to the prone position.

Median time from insertion to demonstration of CR-BSIs was 27.5 days (range, 11.75 to 126.00 days) in the 2019 cases and 16.0 days (range, 11.00–23.50 days) in 2020 (*P* = 0.032).

The comparative aetiologies of the CR-BSI episodes in 2019 and 2020 are shown in Figure 2. We were unable to detect significant differences in the proportion of causative microorganisms of CR-BSIs between the 2019 cases and the 2020 cases.

The attributable mortality of CR-BSIs, in 2019 and 2020 was 28.6% and 40.0%, respectively (*P* = 0.465).

### Table I

Comparison of patients with catheter-related bloodstream infections (CR-BSIs) in 2019 and 2020

| Patients                  | Total   | 2019          | 2020          | P     |
|---------------------------|---------|---------------|---------------|-------|
|                           | N = 81  | N = 23        | N = 58        |       |
| Median age in years, adults (IQR) | 65.0 (57.50–70.50) | 69.00 (58.00–73.00) | 64.50 (56.00–68.25) | 0.168 |
| Median age in years, children (IQR) | 0.0 (0.0–27.50) | 0.0 (0.0–99.00) | 0.5 (0.0–27.50) | 0.629 |
| ICU (%)                   | 68 (83.95) | 15 (65.21) | 53 (91.37) | 0.007 |
| Sex (%)                   | 0.010    |               |               |       |
| Male                      | 60 (74.07) | 12 (52.17) | 48 (82.75) |       |
| Female                    | 21 (25.92) | 11 (47.82) | 10 (17.24) |       |
| Underlying conditions (%) |          |               |               |       |
| COVID-19                  | 45 (55.55) | 0 (0.0) | 45 (77.58) | <0.001 |
| Myocardial infarction      | 2 (2.46) | 0 (0.0) | 2 (3.44) | 1.000 |
| Congestive heart failure   | 1 (1.23) | 0 (0.0) | 1 (1.72) | 1.000 |
| Central nervous system disease | 3 (3.70) | 2 (8.69) | 1 (1.72) | 0.193 |
| Chronic obstructive pulmonary disease | 12 (14.81) | 1 (4.34) | 11 (18.96) | 0.164 |
| Renal dysfunction          | 7 (8.64) | 2 (8.69) | 5 (8.62) | 1.000 |
| Diabetes mellitus          | 18 (22.22) | 5 (21.73) | 13 (22.41) | 1.000 |
| Peptic ulcer disease       | 10 (12.34) | 6 (26.08) | 4 (8.69) | 0.027 |
| Peripheral vascular disease | 2 (2.46) | 1 (4.34) | 1 (1.72) | 0.490 |
| Tumour                    | 16 (19.75) | 11 (47.82) | 5 (8.62) | 0.001 |
| Median length of hospital stay in days (IQR) | 47.00 (29.00–83.50) | 35.00 (19.00–83.00) | 53.00 (34.75–91.75) | 0.059 |
| Median length of ICU stay in days (IQR) | 36.50 (21.25–65.75) | 17.00 (0.00–52.00) | 35.00 (17.00–59.70) | 0.042 |
| Other infections (%)       | 57 (70.37) | 10 (43.47) | 47 (81.03) | 0.002 |
| Mortality (%)              | 32 (39.50) | 7 (30.43) | 25 (43.10) | 0.325 |
| Mortality attributable to CR-BSI (N = 32) (%) | 12 (37.5) | 2 (28.57) | 10 (40.00) | 0.465 |

ICU, intensive care medicine; IQR, interquartile range.
Discussion

Our results demonstrate the substantial quantitative and qualitative impact of the COVID-19 pandemic in CR-BSI. The incidence of CR-BSI increased at least three-fold during the first 3 months of the COVID-19 pandemic in our institution.

The damage caused by the COVID-19 pandemic in different aspects of healthcare and infection control has been devastating, although not yet sufficiently analysed [16–20]. At the beginning of the pandemic, it was already anticipated that patients with severe COVID-19 would develop superinfections, most commonly pneumonia due to nosocomial bacteria and invasive aspergillosis [21,22]. This was confirmed, and, nosocomial secondary infections have been estimated to have occurred in between 7% and 14.3% of hospitalized COVID-19 patients (95% confidence interval, 9.6–18.9%) [23,24]; these infections are more frequent in ICU patients [25,26].

Most common secondary infections in this population are nosocomial pneumonia, mainly associated with mechanical ventilation [27], and bloodstream infections. The most frequent micro-organisms, as expected, were Staphylococcus aureus, Enterococcus spp., Escherichia coli, and Pseudomonas aeruginosa [24]. The infections frequently involved multi-drug-resistant micro-organisms [25–29]. Surprisingly, and despite overuse of antibiotics during the pandemic, preliminary data suggest that the incidence of C. difficile infection decreased in COVID-19 cases [30–33].

Fungal superinfections are also a considerable problem [33,34] and include invasive candidiasis and candidaemia [35], coronavirus-associated pulmonary aspergillosis [36–39], and even Saccharomyces fungaemia [40]. Interestingly, data on episodes of bacteraemia were contradictory in the initial reports of the pandemic period and usually do not specify the policy of blood cultures drawing in different institutions [41,42]. However, it seems clear that prolonged hospital stay, in ICUs, has led most authors to report an increase in episodes of bacteraemia [43].

Our series includes 81 patients with proven CR-BSIs and compared a similar time period in 2019 and 2020; we found that the frequency of CR-BSIs increased three-fold during the COVID-19 period. Very recently, Le Rose et al. [30] reported an increase in the incidence of vascular catheter-related infections during the pandemic. The authors analysed a series of bloodstream infections, with no clear portal of entry, that they related with central-line-associated bloodstream infection (CLABSI). Of the 36 patients who developed CLABSI, six (17%) were in a pre-COVID-19 cohort, while 30 (83%) were in the COVID-19 cohort. The average monthly CLABSI rate increased from 0.40 to 1.7 during COVID-19 (P<0.01). Data from an Italian institution showed that 30% of all BSI episodes during the COVID-19 pandemic originated in endovascular catheters [44]. In our study, this proportion is lower because we included only microbiologically confirmed episodes (CR-BSIs).

In our study 93.7% of the patients with CR-BSI during the pandemic period were in the ICU, in addition these patients received high doses of steroids and most of them were in the prone position, all risk factors for developing more nosocomial infections as described in other studies [43,44]. The use of the prone position to improve ventilation is used in many ICUs, and poses difficulties for both insertion and care of endovascular catheters and has been related to higher risk of CVC infectious complications [45,46].

Patients who developed CLABSI in the pre-COVID-19 cohort had a median length of stay of 19 days compared with patients in the COVID-19 cohort, who had a median length of stay of 27 days (P=0.12) [30]. However, in our study, despite a longer ICU stay, episodes of CR-BSI occurred earlier after catheter insertion than in 2019. If we combine these findings with an increased rate of contaminated blood cultures and a higher
proportion of CR-BSI caused by coagulase-negative staphylococci, we can conclude that catheter insertion and care worsened. Other risk factors reported in the literature include the use of corticosteroids and tocilizumab, although we have little insight into the role that other risk factors may have in these patients [44].

In our study, the micro-organisms causing CR-BSI were mainly Gram-positive. Other authors, analysing the aetiologies of CLABSI in a COVID-19 cohort, reported that 53.3% were caused by Gram-positive bacteria, followed by 26.7% fungal and 20% Gram-negative bacteria [30].

The main limitation of our study is that it was performed in a single hospital and further studies with multi-centre data would be welcome. While our study reflects findings from a single hospital and further studies with multi-centre data would be welcome. While our study reflects findings from a single hospital, we believe that it appropriately quantifies a problem that may well have affected many centres throughout the world.

We hope that our findings will contribute to urge health professionals to immediately reinforce nosocomial infection control measures. These figures should and can be lowered [5,47].

**Acknowledgements**

We thank Thomas O’Boyle for his help in the preparation of the manuscript.

**Author contributions**

E.B. and M.J.P.G. participated in the conception and design of the study, carried out the analysis, interpreted the data and drafted the manuscript. C.S., P.M.R., M.V., M.O. and PM collected the samples and data and participated in drafting the manuscript. All of the authors read and approved the final version of the manuscript.

**Conflict of interest statement**

The authors declare no conflicts of interest.

**Funding sources**

This study was supported in part by CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain; by grants from the ISCIII (PI20/00575) II-PI-ENF-1-2019 and the European Regional Development Fund (FEDER) “A way of making Europe”. The funders had no role in the study preparation for the next pandemic. J Clin Invest 2020;130:4543–5.

**References**

[1] Stevens V, Geiger K, Concannon C, Nelson RE, Brown J, Dumyat G. Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections. Clin Microbiol Infect 2014;20:O318–24.

[2] Ferrer C, Almirante B. Venous catheter-related infections. Enferm Infecc Microbiol Clin 2014;32:115–24.

[3] Rosenthal VD, Bat-Erdene I, Gupta D, Belkebir S, Rajhans P, Zand F, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2012-2017: Device-associated module. Am J Infect Control 2020;48:423–32.

[4] Picturri M, Pinelli F. Recommendations for the use of vascular access in the COVID-19 patients: an Italian perspective. Crit Care 2020;24:269.

[5] Timsit JF, Baleine J, Bernard L, Calvino-Gunther S, Darmon M, Dellamonica J, et al. Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit. Ann Intensive Care 2020;10:118.

[6] Ceylan Z. Estimation of COVID-19 prevalence in Italy, Spain, and France. Sci Total Environ 2020;729:138817.

[7] Kazemi-Karyani A, Safari-Faramani R, Amini S, Ramezani-Doroh V, Berenjian F, Dizaj M, et al. World one-hundred days after COVID-19 outbreak: incidence, case fatality rate, and trend. J Educ Promot Health Prevent 2020;9:199.

[8] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.

[9] Huang L, Wang Y, Liu J, Ye P, Chen X, Xu H, et al. Factors influencing anxiety of health care workers in the radiology department with high exposure risk to COVID-19. Med Sci Monit 2020;26:e926008.

[10] Sorbello M, El-Boghdady K, Di Giacinto I, Cataldo R, Esposito C, Falcetta S, et al. The italian coronavirus disease 2019 outbreak: recommendations from clinical practice. Anaesthesia 2020;75:724–32.

[11] Scoppettuolo G, Biasucci DG, Picturri M. Vascular access in COVID-19 patients: smart decisions for maximal safety. J Vasc Access 2020;21:408–10.

[12] Cataldo MA, Tetaj N, Selleri M, Marchioni L, Capone A, Caraffa E, et al. Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming “collateral effect. J Glob Antimicrob Resist 2020;23:290–1.

[13] Bonazzetti C, Morena V, Giacomelli A, Oreni L, Casalini G, Galimberti LR, et al. Unexpectedly high frequency of enterococcal bloodstream infections in coronavirus disease 2019 patients admitted to an Italian ICU: an observational study. Crit Care Med 2021;49:e31–40.

[14] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.

[15] O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011;52:e162–93.

[16] Bali S, Banerjee A, Berry C, Boyle JR, Bray B, Bradlow W, et al. Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. Heart 2020;106:1890–7.

[17] Shapiro LI, Kajita GR, Arnstén JH, Tomer Y. Toward better preparedness for the next pandemic. J Clin Invest 2020;130:4543–5.

[18] Cohen A, Selles RW, De Ridder WA, Ter Stege MHP, Souer JS, Wouters RM. What is the impact of the COVID-19 pandemic on quality of life and other patient-reported outcomes? An analysis of the hand-wrist study cohort. Clin Orthop Relat Res 2021;479:335–45.

[19] Tan E, Song J, Deane AM, Plummer MP. Global impact of coronavirus disease 2019 infection requiring admission to the ICU: a systematic review and meta-analysis. Chest 2021;159:524–36.

[20] Harrison D, Morandi A, El Sahly H, Bozkurt B, Jneid H. Impact of the SARS-CoV-2 pandemic on health-care workers. Hosp Pract 2020;48:161–4.

[21] Dupont D, Menotti J, Turc J, Miossec C, Wallet F, Richard JC, et al. Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19). Med Mycol 2021;59:110–4.

[22] Clancy CJ, Nguyen MH. COVID-19, superinfections and antimicrobial development: what can we expect? Clin Infect Dis 2021;71:2736–43.

[23] Langford BJ, So M, Raybardhan S, Leung V, Westwood D, Oreni LA, et al. Bacterial co-infection and secondary microbial development: what can we expect? Clin Infect Dis 2021;71:2736–43.
and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021;27:83–8.

[25] Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect 2020;9:1958–64.

[26] Barrasa H, Rello J, Tejada S, Martin A, Balziskueta G, Vinuesa C, et al. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. Anaesth Crit Care Pain Med 2020;39:553–61.

[27] Ceccharelli G, Alessandri F, Oliva A, Dell’Isola S, Rocco M, Ruberto F, et al. Superinfections in patients treated with Teicoplanin as anti-SARSCoV2 agent. Eur J Clin Invest 2021;51:e13418.

[28] Nori P, Cowman K, Chen V, Bartash R, Szymczak W, Madaline T, et al. Bacterial and fungal co-infections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021;42:84–8.

[29] Bentivegna E, Alessio G, Spuntarelli V, Luciani M, Santino I, Ponce-Alonso M, Saéz de la Fuente J, Rinco´n -Carlavilla A, Mor-

[30] LeRose J, Sandhu A, Polistico J, Ellsworth J, Cranis M, Jabbo L, et al. Impact of the COVID-19 response on central line associated bloodstream infections and blood culture contamination rates in tertiary care centers in the Greater Detroit area. Infect Control Hosp 2021;42:997–1000.

[31] Ponce-Alonso M, Sáez de la Fuente J, Rincón-Carlavilla A, Morn-

[32] Bentivegna E, Alessio G, Spuntarelli V, Luciani M, Santino I, Simmaco M, et al. Impact of COVID-19 prevention measures on risk of health care-associated Clostridiodile difficile infection. Infect Control Hosp Epidemiol 2021;42:406–10.

[33] Heard KL, Hughes S, Mughal N, Moore LSP. COVID-19 and fungal superinfection. Lancet Microbe 2020;1:e107.

[34] Nestler M, Godbou P, Lee K, Kim J, Noda AJ, Taylor P, et al. Fungal superinfection in patients with COVID-19: role of anti-fungal stewardship? Am J Infect Control 2021;49:279–80.

[35] Arastehfar A, Carvalho A, Nguyen MH, Hedayati MT, Netea MG, Perlin DS, et al. COVID-19-associated Candidiasis (CAC): an underestimated complication in the absence of immunological predispositions? J Fungi (Basel) 2020;6:211.

[36] Bassetti M, Giacobbe DR, Grecchi C, Rebuffi C, Zuccaro V, Scudeller L. Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: a systematic review with qualitative evidence synthesis. J Infect 2020;81:131–46.

[37] Blaize M, Mayaux J, Nabet C, Lampros A, Marcelin AG, Thellier M, et al. Fatal invasive Aspergillosis and coronavirus disease in an immunocompetent patient. Emerg Infect Dis 2020;26:1636–7.

[38] Arastehfar A, Carvalho A, van de Veendonk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 Associated pulmonary aspergillosis (CAPA) — from immunology to treatment. J Fungi (Basel) 2020;6:91.

[39] Machado M, Valerio M, Álvarez-Uría A, Olmedo M, Veintimilla C, Padilla B, et al. Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. Mycoses 2021;64:132–43.

[40] Ventoulis I, Sarmourli T, Amoiridou P, Mantzana P, Exindari M, Gioula G, et al. Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU. J Fungi (Basel) 2020;6:98.

[41] Sepulveda J, Westblad LF, Whittier S, Satlin MJ, Greendyke WG, Aaron JG, et al. Bacteremia and blood culture utilization during COVID-19 surge in New York City. J Clin Microbiol 2020;58. e00875-20.

[42] Yu D, Ininbergs K, Hedman K, Giske CG, Strålin K, Özenç V. Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19. PLoS One 2020:15:e024253.

[43] Engsbro AL, Israelsen SB, Pedersen M, Tingsgaard S, Lisby G, Andersen C, et al. Predominance of hospital-acquired bloodstream infection in patients with Covid-19 pneumonia. Infect Dis (Lond) 2020;52:919–22.

[44] Giacobbe DR, Battaglini D, Ball L, Brunetti I, Bruzzone B, Codda G, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest Oct 2020;50:e13319.

[45] Yang X, Yu Y, Xu J, Shi H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.

[46] Louis G, Belveyre T, Jacquot A, Hochard H, Aliaa N, Kimmoun A, et al. Infection related catheter complications in patients undergoing prone positioning for acute respiratory distress syndrome: an exposed/unexposed study. BMC Infect Dis 2021;21:534.

[47] Chun TT, Judelson DR, Rigberg D, Lawrence PF, Cuff R, Shalhub S, et al. Managing central venous access during a health care crisis. J Vasc Surg 2020;72:1184–95.